Management of endometrial hyperplasia

X. International Turkish – German Gynecology Congress
April 30th and May 4th, 2014, Antalya
TAJEV (Turkish - German Gynecological Education and Research Foundation)

Prof. Dr. S. Sinan ÖZALP
Eskişehir Osmangazi Un. Faculty of Medicine
Department of Obstetrics and Gynecology
Eskişehir - Turkey
Endometrial hyperplasia (EH) - Importance

- Cause of AUB
- Risk factor for the development of endometrial cancer (EC)

Endometrial hyperplasia (EH) - Definition

- EH is an abnormal proliferation of the endometrium, greater than the normal proliferation that occurs during the menstrual cycle
- In EC, prolonged estrogenic stimulation plays a causal role
Epidemiology of EH

- Women aged 18 to 90 over an 18-year period, the overall incidence of EH was 133 per 100,000 woman-years.

- The diagnosis is most commonly made in women age 50 to 54 years.

- The incidence of simple and complex EH without atypia were highest in women age 50 to 54 years.

- The rate of AEH was highest in women age 60 to 64 (56 per 100,000 woman-years).

Risk fakters for EH

- Same as those for EC
- Obesity, unopposed estrogen, DM, and nulliparity
Clinical presentation

- EH typically presents with AUB and is most common in women who are postmenopausal and with increasing age in premenopausal women.

- Occasionally, women with no abnormal uterine bleeding present with abnormal findings on cervical cytology or TVUS findings in postmenopausal women.
Evaluation of women with suspected EH

- Physical and pelvic exam
- TVUS to exclude another etiology of AUB or to assess endometrial thickness in postmenopausal women
- Evaluation is the same as for women with suspected EC
Diagnosis of endometrial precancer

- Hysteroscopy does not significantly increase detection of occult cancers

- Moreover, not all precancerous lesions can be visualized by hysteroscopy

- Current diagnostic schema should include assessment of sample adequacy
Diagnosis of EH

- AUB symptoms may be due to an etiology other than EH
- TVUS, sonohysterography, or diagnostic hysteroscopy should be performed to exclude other lesions (myomas, endometrial polyp)
BMI is predictive of sonographic endometrial stripe thickness, which in turn is predictive of EH in patients with PCOS

For every 1-mm increase in endometrial stripe, the odds ratio of hyperplasia increased by 1.48 (95% confidence interval, 1.04-2.10)

Endometrial thickness and prediction of EH

- Evaluation of endometrial sampling in asymptomatic, bleeding-free postmenopausal women with endometrial thickness greater or equal to 5 mm
- Retrospective study, mean endometrial stripe thickness was 8.7 mm
- 5 cases of EC (0.9%) and 65 (12.2%) cases of simple/complex atypical hyperplasia were diagnosed
- 106 investigations were performed to detect one case of EC

It is not well established

The case control study reported that the average time to diagnosis of cancer was six years in women with all types of EH

EC risk among women EH: the 34-year experience

- Classifying EH as simple hyperplasia (SH) vs complex hyperplasia (CH), and nuclear atypia (simple atypical hyperplasia (SAH) vs complex atypical hyperplasia (CAH))

- AH significantly increased carcinoma risk (RR=14)

- Risk was highest 1-5 years after AH

- Remained elevated 5 or more years after AH

- Progression risks for SH (RR=2.0) and CH (RR=2.8) were substantially lower

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dosage and length</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPA</td>
<td>10-20 mg daily or cyclic 12-14 d/mo</td>
</tr>
<tr>
<td>DMPA</td>
<td>150 m IM every 3 month</td>
</tr>
<tr>
<td>Micronized vaginal progesterone</td>
<td>100-200 mg daily or cyclic 12-14 d/mo</td>
</tr>
<tr>
<td>LNG containing IUD</td>
<td>1-5 y</td>
</tr>
</tbody>
</table>
Progestin treatment for women with the low risk of progression to EC

- Regression of hyperplasia
  - 80–90% of subjects receiving MPA, 10 mg daily for 12–14 days per month
Effect of LNG IUD with oral MPA on simple EH and fertility preservation

- Endometrial thickness was reduced in both groups \( (p < 0.001) \), but further reduction in LNG group was seen.

- Side-effects of MPA were more and reached significance \( (p < 0.003) \).

- The rate of satisfaction with LNG was higher than MPA \( (p < 0.048) \).

Identification of precursor lesions of EAC

- The classification systems most widely used
  - Use of architectural features and cytologic atypia, termed atypical endometrial hyperplasia (AEH)
  - Use of quantitative morphologic measures associated with clonality, and terminology, endometrial intraepithelial neoplasia (EIN) is defined
## Endometrial precancer Classification Systems

**WHO94**

<table>
<thead>
<tr>
<th>Category</th>
<th>EAC Risk %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple hyperplasia without atypia</td>
<td>1</td>
</tr>
<tr>
<td>Complex hyperplasia without atypia</td>
<td>3</td>
</tr>
<tr>
<td>Simple atypical hyperplasia</td>
<td>8</td>
</tr>
<tr>
<td>Complex atypical hyperplasia</td>
<td>29</td>
</tr>
</tbody>
</table>

- Categories are descriptive in nature
- Interpretation is subjective
- Indicate poor reproducibility
- Do not suggest specific management algorithms
<table>
<thead>
<tr>
<th><strong>Diameter</strong></th>
<th>minimum 1 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Architecture</strong></td>
<td>area of glands exceeds the area of stroma</td>
</tr>
<tr>
<td><strong>Cytology</strong></td>
<td>changed relative to background</td>
</tr>
<tr>
<td><strong>Exclude mimics</strong></td>
<td>polyps, secretory endometrium, effects of exogenous estrogen and cancer</td>
</tr>
</tbody>
</table>
## EIN nomenclature

<table>
<thead>
<tr>
<th>EIN nomenclature</th>
<th>Topography</th>
<th>Functional Category</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unopposed</td>
<td>Diffuse</td>
<td>Estrogen effect</td>
<td>Hormonal</td>
</tr>
<tr>
<td>Estrogens (EH)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EIN</td>
<td>Focal, later diffuse</td>
<td>Precancer</td>
<td>Hormonal or surgery</td>
</tr>
<tr>
<td>Cancer</td>
<td>Focal, later diffuse</td>
<td>Cancer</td>
<td>Surgery stage based</td>
</tr>
</tbody>
</table>
Endometrial precancer Classification Systems
WHO94 and EIN

- EIN diagnosis has been confirmed as prognostic in several retrospective and one prospective study
- Clinical outcome prediction and inter-observer reproducibility using the EIN system can be greater than for the WHO94
- Case-control studies reviewing histopathology of either AEH or EIN demonstrate positive predictive value of both of these diagnoses
- Both diagnostic schema are limited by the quality of the diagnostic tissue specimen
Many women with AEH have coexistent EC. 

A literature review noted the frequency of concurrent EC among patients with AEH ranged from 17 to 52% across studies.

GOG 167, the largest prospective study to date, was designed to assess the rate of concurrent carcinoma in hysterectomies performed immediately after a tissue diagnosis of AEH.

Concurrent EC was diagnosed in 123 (42.6%) of cases, 43 of which had high risks including myoinvasion or grade 2 or grade 3 carcinomas.

Coexistent EC with AEH

- EC associated with AEH/EIN diagnosed in hysterectomy specimen are usually low grade, early stage lesions that have a low risk of LVI
- The risk of a concurrent high-risk uterine carcinoma (high grade, high stage) in women with a biopsy diagnosis of AEH ranges from 5–7%

The primary objectives with EIN/AEH are:
- Ruling out a concurrent EC
- Prevention of progression to EC

Management of AEH/EIN can be surgical and non-surgical.
Intraoperative assessment of AEH/EIN

- At minimum, evaluation should include opening the specimen to assess for gross evidence of a tumor mass or myoinvasion.
- If invasive cancer is suspected, the pathologist should exercise judgment in deciding if frozen section analysis is indicated.
The distinction between AEH/EIN and well-differentiated endometrial carcinoma can be difficult even for experienced pathologists.

Patients should be staged when an underlying carcinoma is identified.

Otherwise management decisions should be made based on final diagnoses rendered on formalin-fixed tissue.
Intraoperative assessment of AEH/EIN

- Intraoperative assessment of tumor grade and final histologic diagnoses made on permanent sections ranges from 40–70%

- Intraoperative assessment of depth of myoinvasion is congruent with final histopathologic diagnoses in the range of 70% of cases
Management of AEH/EIN

- Surgical options include abdominal, vaginal, and minimally invasive procedures (laparoscopy or robotic surgery)
- Hysterectomy with or without BSO is standard
- Total hysterectomy is the current standard of care for AEH/EIN
Without hysterectomy and nonsurgical management of AEH/EIN

- The therapeutic goal
  - Complete clearance of disease
  - Reversion to normal endometrial function
  - The prevention of invasive EC
Endometrial ablation for the management of AEH/EIN

- Not recommended for the treatment of AEH/EIN
  - There are no available methods to confirm the completeness of ablation
  - Subsequent adhesions may render the cavity partly inaccessible for follow-up
Nonsurgical Management of AEH/EIN

- Progestins
- SERMS
- Aromatase inhibitors
- Sulfatase inhibitors
- GNRH antagonists
Nonsurgical Management of AEH/EIN

- Progestins
  - Acceptable toxicity profile
  - Option for any patient wanting to retain fertility
  - Option for any patient who desires uterine retention
  - Option for elderly patients with medical comorbidities

- Therapy have limitations, neither the dose nor the schedule for progestational agents has been well standardized
Effectiveness of progestin treatment for AEH/EIN

- Histologic examination after completion of therapy and a withdrawal bleed provides the greatest information on response

- Full examination of the endometrium is required to measure regression, persistence, or progression of EIN. Examination of the entire uterus after hysterectomy is considered the "gold standard", but is not an option for patients who receive non-surgical management.
A cohort study of 219 women with complex nonAEH or AEH who were treated and achieved initial regression with LNG-IUS or oral progestogens and followed >5 years.

Relapse of EH occurred in 13.7% of women treated with LNG-IUS compared with 30.3% of women treated with oral progestogens, OR=0.34, (0.005)

Effectiveness of progestin treatment for AEH/EIN, with oral progestin or LNG-IUD

- Treatment with an oral progestin or LNG-IUD is a reasonable first option
- Treatment should be continued for 6 months or more unless progression is identified
- Longitudinal endometrial sampling, either by curettage or biopsy, at 3–6 month intervals, until a minimum of 3 negative biopsies are obtained
- If persistence or progression to carcinoma is detected, hysterectomy will be performed
22 studies, totaling 351 patients were used to assess pregnancy rate; 111 subjects (32%) had one pregnancy or more.

Among the 263 patients used to assess progression rate, 39 (15%) had a tumor with at least myometrial invasion on the hysterectomy specimen.

Fertility-sparing management should not be contraindicated in older patients with previous infertility or obesity.

EH without atypia is treated with progestins

Total hysterectomy is curative of AEH/EIN and provides a definitive assessment of a concurrent EC

If hysterectomy is performed for AEH/EIN, intraop. assessment of the uterine specimen for occult EC is preferred

Evaluation by a qualified pathologist with gross examination with or without frozen section is necessary

Endometrial ablation is not recommended for AEH/EIN

Follow-up of women treated hormonally should include multiple endometrial samplings
Management of endometrial hyperplasia

X. International Turkish – German Gynecology Congress
April 30th and May 4th, 2014, Antalya
TAJEV (Turkish - German Gynecological Education and Research Foundation)

Prof. Dr. S. Sinan ÖZALP
Eskişehir Osmangazi Un. Faculty of Medicine
Department of Obstetrics and Gynecology
Eskişehir - Turkey
Tedavide progesteron – progestinler

- Düşük doz, ayda 12-14 gün
  - MPA, 10-20 mg/gün
  - Nor ethidron asetat, 5 mg/gün
  - Mikronize progesteron (oral, vajinal) 200 mg/gün
  - Megesterol asetatet, 20-40 mg/gün

- Yüksek doz, ayda 21 gün
  - MPA, 40-100 mg /gün
  - Mikronize progesteron (oral, vajinal) 300-400 mg/gün
  - Megesterol asetatet, 80-160 mg /gün
<table>
<thead>
<tr>
<th>Ürün</th>
<th>Açıklama</th>
<th>Fiyat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNG-IUS, Mirena</td>
<td></td>
<td>239.44 TL</td>
</tr>
<tr>
<td>Progesteron</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progestan 100 mg</td>
<td>30 kap/kutu, 13.53 TL</td>
<td></td>
</tr>
<tr>
<td>Progestan 200 mg</td>
<td>30 kap/kutu, 26.97 TL</td>
<td></td>
</tr>
<tr>
<td>Progestan 50 mg</td>
<td>ampul, 5x1 amp, 18.18 TL</td>
<td></td>
</tr>
<tr>
<td>Progynex kapsül</td>
<td>100 mg, 30 kap/kutu, 13.53 TL</td>
<td></td>
</tr>
<tr>
<td>Progynex kapsül</td>
<td>200 mg, 30 kap/kutu, 26.97 TL</td>
<td></td>
</tr>
<tr>
<td>Progynex ampul</td>
<td>50 mg, 5x1 amp, 19.70 TL</td>
<td></td>
</tr>
</tbody>
</table>
Türkiye’deki Preperatlar – fiyatları 01.04.2014

- **Progesteron analogları**
  - Didrogesteron (Duphastonon 10 mg, 20 tab/kutu), 9.97 TL
  - MPA (Tarlusal 5mg, 12 tab/kutu, 3.87 TL
  - Nomegestesterol Asetat (Lutenyl 5mg, 10 tab/kutu), 7.82 TL
  - Megesterol asetet (Megace 160 mg, 30 tab/kutu) 44,03 TL

- **Testosteron analogları**
  - Noretisteron (Primolut-N 5mg, 30 tab/kutu), 9.71TL
  - Linestrenol (Orgametril 5mg, 30 tab/kutu), 8.28 TL